dc.contributor.author | Fosså, Sophie Dorothea | |
dc.contributor.author | Aas, Kirsti | |
dc.contributor.author | Muller, Christoph Rainer | |
dc.contributor.author | Jerm, Marianne Brenn | |
dc.contributor.author | Tandstad, Torgrim | |
dc.contributor.author | Lilleby, Wolfgang | |
dc.contributor.author | Kvåle, Rune | |
dc.contributor.author | Gulbrandsen, Johanne | |
dc.contributor.author | Haug, Erik Skaaheim | |
dc.contributor.author | Myklebust, Tor Åge | |
dc.date.accessioned | 2022-11-29T14:57:31Z | |
dc.date.available | 2022-11-29T14:57:31Z | |
dc.date.created | 2021-01-04T14:42:08Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Radiotherapy and Oncology. 2020, 155 33-41. | en_US |
dc.identifier.issn | 0167-8140 | |
dc.identifier.uri | https://hdl.handle.net/11250/3034819 | |
dc.description.abstract | Background: More studies are needed to document nation-wide use and effectiveness of curative definitive radiotherapy (Def-RT) in the treatment of prostate cancer (PCa).
Patients and methods: For 38,960 men diagnosed with PCa without distant metastases from 2006 to 2015 data from the Norwegian Prostate Cancer Registry and a national radiotherapy database (NoRadBase) was analyzed. Overall survival and PCa-specific mortality were described comparing EQD-2 < 74 Gy (“low-dose”) with EQD-2 ≥ 74 Gy (“escalated dose”).
Results: Use of Def-RT decreased (27–24%) whereas the proportion of radical prostatectomies (RPs) increased (31–38%). In high-risk patients the use of RP doubled (18–36%), while the proportion of Def-RT remained stable (about 35%). Before 2010, almost a quarter of patients received low-dose Def-RT with gradual increase of escalated Def-RT thereafter. Escalated Def-RT was associated with significantly more favorable 10-year PCa-specific mortality (4.4% [95% CI: 2.7–10.7%]) than observed after low-dose Def- RT (8.8% [95% CI: 6.2–9.8%), with the most beneficial effects in high-risk patients. Our analyses indicated the need to expand the NoRadBase by consensus-based quality measures.
Conclusion: In this nationwide cohort, the overall use of Def-RT decreased slightly. In high-risk patients the provision of Def-RT remained stable and was accompanied by doubling of patients with RP and reduction of a “no curative treatment” strategy. Escalated dose Def-RT significantly reduced 10-year PCa-specific mortality compared to low-dose Def-RT. Aiming for cancer care equity national radiotherapy registries for PCa should regularly monitor data based on consensus-based quality measures enabling feedback to the responsible hospitals. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Definitive radiotherapy for prostate cancer in Norway 2006-2015: Temporal trends, performance and survival | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 33-41 | en_US |
dc.source.volume | 155 | en_US |
dc.source.journal | Radiotherapy and Oncology | en_US |
dc.identifier.doi | 10.1016/j.radonc.2020.10.022 | |
dc.identifier.cristin | 1864956 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |